-- On track to file IND and/or CTA for Wilson Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 -- -- Ongoing engagement with FDA for ...
The biotechnology firm Prime Medicine is approaching what could be its most definitive period. Following its 2025 annual results, the company is shifting its strategic emphasis from initial clinical ...
CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic ...
Prime Medicine, Inc. (NASDAQ:PRME) is among the 12 Best Genomics Stocks to Invest In. Prime Medicine, Inc. (NASDAQ:PRME) stated on December 7, 2025, that the New England Journal of Medicine has ...
Hosted on MSN
LifeSci Capital initiates Prime Medicine (PRME), highlights one-and-done potential in liver and lung diseases
Prime Medicine Inc. (NASDAQ:PRME) is one of the best biotech penny stocks to buy according to analysts. On December 23, LifeSci Capital initiated coverage of Prime Medicine with an Outperform rating ...
-- Prime Medicine reported cash, cash equivalents, investments, and restricted cash of $191M providing cash runway into 2027 -- CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results